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Type 2 diabetic nephropathy is one of the major long-term
microvascular complications occurring in nearly 40% of
diabetic patients and also a major cause of end-stage kidney
disease (ESKD) throughout the world. It is assumed that the
number of type 2 diabetes and diabetic nephropathy patients
isincreasingandthatmoreandmorepatientswillexperience
progressive renal disease due to lack of eﬀective treatments.
The pathogenesis of type 2 diabetic nephropathy includes
genetic, metabolic (hyperglycemic), and/or hemodynamic
factors such as glomerular hypertension and associated renal
hypertrophy. There are many progressive factors in patients
withtype2diabeticnephropathy,butfewifanyspeciﬁctreat-
ments for human diabetic nephropathy based on the mecha-
nisms of disease initiation and progression have been clearly
identiﬁed. Thus, it is important to investigate and deter-
mine pathogenesis (mechanisms of initiation and/or pro-
gression) and treatments using various experimental models
of type 2 diabetic nephropathy.
This special issue contains 11 papers, based on studies of
various animal models, cell cultures, and human samples.
In the paper entitled “Dietary restriction ameliorates di-
abetic nephropathy through anti-inﬂammatory eﬀects and reg-
ulation of the autophagy via restoration of Sirt1 in diabetic
Wistar fatty (fa/fa) rats: a model of type 2 diabetes,” M. Kitada
et al. examined the renoprotective eﬀects of dietary restric-
tion (DR) in Wistar fatty (fa/fa) rats (WFRs). DR amelio-
rated renal abnormalities including inﬂammation in WFRs.
The decrease in Sirt1 levels, increase in acetylated-NF-κB,
andimpairedautophagyinWFRswereimprovedbyDR.The
authorsconcludedthatDRexertedanti-inﬂammatoryeﬀects
and improved the dysregulation of autophagy through the
restoration of Sirt1 in the kidneys of WFRs, which resulted
in the amelioration of renal injuries in type 2 diabetes.
In the paper entitled “High glucose increases metallothio-
nein expression in renal proximal tubular epithelial cells,” D.
Ogawa et al. found that the renal tissues in adult male di-
abetic rats induced by streptozotocin were stained with anti-
bodies for MT-1/-2. MT-1/-2 expression was also evaluated
in mProx24 cells, a mouse renal proximal tubular epithelial
cell line, stimulated with high glucose medium and pre-
treated with the antioxidant vitamin E. These observations
suggest that MT-1/-2 is induced in renal proximal tubular
epithelial cells as an antioxidant to protect the kidney from
oxidative stress and that it may oﬀer a novel therapeutic
target against diabetic nephropathy.
In the paper entitled “Targeted proteomics of isolated glo-
meruli from the kidneys of diabetic rats: sorbin and SH3 do-
main containing 2 is a novel protein associated with diabe-
tic nephropathy,” S. Nakatani et al. examined the protein ex-
pression in the isolated glomeruli from spontaneous type 2
diabetic (OLETF) rats and their age-matched control litter-
mates (LETO) in the early and proteinuric stages of diabetic
nephropathyusingQSTAREliteLC-MS/MS.SorbinandSH3
domain containing 2 (SORBS2) was signiﬁcantly upregu-
lated in both stages of diabetic nephropathy. Immunohisto-
chemical and quantitative PCR analyses revealed upregula-
tionofSORBS2inthepodocytesofglomeruliofOLETFrats.
These ﬁndings suggested that SORBS2 may be associated
with the development of diabetic nephropathy possibility by
reorganization of actin ﬁlaments.
In the paper entitled “Role of T cells in type 2 diabetic
nephropathy,” C.-C. Wu et al. reviewed the current infor-
mation concerning the role of T cells in the development
and progression of type 2 diabetic nephropathy. Speciﬁc
emphasis is placed on the potential interaction and con-
tribution of the T cells to renal damage. The therapeutic2 Experimental Diabetes Research
strategies involving T cells in the treatment of type 2 diabetic
nephropathy are also reviewed. Improving knowledge of the
recognition of T cells as signiﬁcant pathogenic mediators
in diabetic nephropathy reinforces the possibility of ﬁnding
new potential therapeutic targets that may be translated into
future clinical treatments.
In the paper entitled “Involvement of F-Actin in chaper-
onin-containing t-complex 1 beta regulating mouse mesangial
cell functions in a glucose-induction cell model,” J.-S. Chen
et al. investigated the role of chaperonin-containing t-
complex polypeptide 1 beta (CCT2) in the regulation of
mouse mesangial cell (mMC) contraction, proliferation and
migration with ﬁlamentous/globular- (F/G-) actin ratio
under high glucose induction. Major results were as follows:
(1) low CCT2 or high glucose showed the ability to attenuate
F/G-actin ratio, (2) groups with low F/G-actin ratio all
showed less cell contraction, and (3) suppression of CCT2
may reduce the proliferation and migration which were ori-
ginally induced by high glucose. The authors concluded that
CCT2 can be used as a speciﬁc regulator for mMC contrac-
tion, proliferation, and migration aﬀected by glucose, in
which the mechanism may involve the alteration of F-actin,
particularly for cell contraction.
In the paper entitled “Diabetic nephropathy amelioration
by a low-dose sitagliptin in an animal model of type 2
diabetes (Zucker diabetic fatty rat),” C. Mega et al. performed
studies to assess the eﬀect of chronic low-dose sitagliptin, a
dipeptidyl peptidase 4 inhibitor, on metabolic proﬁle and on
renal lesions in a rat model of type 2 diabetic nephropathy,
the Zucker diabetic fatty (ZDF) rat. The authors concluded
that chronic low-dose sitagliptin treatment was able to
ameliorate diabetic nephropathy, which might represent a
key step forward in the management of type 2 diabetes and
this serious complication.
Inthepaperentitled“Roleofmindinindiabeticnephropa-
thy,”M.Murakoshietal.suggestedthatcertaininﬂammatory
biomarkers should be useful for diagnosis or monitoring
of diabetic nephropathy. Mindin (spondin 2) is a member
of the mindin-/F-spondin family of secreted extracellular
matrix (ECM) proteins. Recent studies have showed that
mindin is essential for initiation of innate immune response
and represents a unique pattern-recognition molecule in the
ECM. The authors previously demonstrated that the levels of
urinary mindin in patients with type 2 diabetes were higher
than those in healthy individuals. Therefore, the authors
suggest that urinary mindin may be a potent biomarker for
the development of diabetic nephropathy.
Inthepaperentitled“Newexperimentalmodelsofdiabetic
nephropathy in mice models of type 2 diabetes: Eﬀorts to
replicate human nephropathy,” M. J. Soler et al. explained
that the generation of new experimental models of diabetic
nephropathy created by crossing, knockdown, or knockin
of genes continues to provide improved tools for studying
diabetic nephropathy. These models provide an opportunity
to search for new mechanisms involving the development
of diabetic nephropathy, but their shortcomings should be
recognized as well. Moreover, it is important to recognize
that the genetic background has a substantial eﬀect on the
susceptibility to diabetes and kidney disease development in
the various models of diabetes.
In the paper entitled “Osmolarity and glucose diﬀer-
entially regulate aldose reductase activity in cultured mouse
podocytes,” B. Lewko et al. examined whether aldose reduc-
tase (AR), the enzyme implicated in diabetic complications
in diﬀerent tissues, is modulated by high glucose and osmo-
larity in podocytes. Hyperosmolarity acutely stimulated AR
expression and activity, with subsequent increase of AR
expressionbutdecreaseofactivity.Highglucosealsoelevated
AR protein level; however, this was not accompanied by
respective enzyme activation. Furthermore, high glucose
appeared to counteract the osmolarity-dependent activation
of AR. The authors concluded that AR is modulated by high
glucose and increased osmolarity in a diﬀerent manner in
podocytes. Posttranslational events may aﬀect AR activity
independent of enzyme protein amount. Activation of AR in
podocytes may be implicated in diabetic podocytopathy.
In the paper entitled “Signaling mechanisms in the regu-
lation of renal matrix metabolism in diabetes,” M. M. Mariap-
panreviewedthatmTOR-(mammaliantargetofrapamycin-)
regulated pathways are pivotal in orchestrating high-glu-
cose-induced production of extracellular matrix (ECM) pro-
teins leading to functional and structural changes in the
kidney culminating in adverse outcomes. Understanding sig-
naling pathways that inﬂuence individual matrix protein ex-
pression could lead to the development of new interven-
tional strategies. This review will highlight some of the
diverse components of the signaling network stimulated by
hyperglycemiawithanemphasisonextracellularmatrixpro-
tein metabolism in the kidney in diabetes.
In the paper entitled “An angiotensin II type 1 receptor
blocker, prevents renal injury via inhibition of the Notch
pathway in Ins2 Akita diabetic mice,” M. Koshizaka et al.
showedthattelmisartaninhibitedtheangiotensinII-induced
increased expression of transforming growth factor β and
vascular endothelial growth factor A which could directly
activate the Notch signaling pathway in cultured podocytes.
The authors indicated that the telmisartan prevents diabetic
nephropathy through the inhibition of the Notch pathway.
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